Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
A comprehensive clinical guide to using Farxiga (dapagliflozin) after bariatric surgery, covering pharmacokinetics, DKA risk, dosing, monitoring, and guideline recommendations with primary literature citations.
Read clinical reviewA clinician-reviewed, week-by-week guide to what Farxiga (dapagliflozin) does in your first 30 days, covering blood sugar, weight, blood pressure, urinary side effects, and when to call your doctor.
Read clinical reviewDoes Farxiga (dapagliflozin) reduce appetite or change food cravings? A PharmD/MD-level review of the mechanisms, clinical trial data, and what patients can realistically expect.
Read clinical reviewA clinical deep-dive into how dapagliflozin (Farxiga) affects bone mineral density, fracture risk, and skeletal metabolism in patients with type 2 diabetes, heart failure, and CKD, with primary-literature citations and actionable clinical guidance.
Read clinical reviewA physician-level review of the dapagliflozin (Farxiga) cancer risk signal, covering bladder cancer concerns from early trials, post-marketing surveillance data, FDA label updates, and how DAPA-HF and DECLARE-TIMI 58 inform current prescribing decisions.
Read clinical reviewA physician-reviewed deep dive into dapagliflozin's long-term cardiovascular effects, covering DAPA-HF, DECLARE-TIMI 58, DAPA-CKD, and current prescribing guidance for HFrEF, HFpEF, and CKD populations.
Read clinical reviewA physician-reviewed deep dive into dapagliflozin (Farxiga) and cognitive function, covering cardiovascular mechanisms, glucose variability, inflammation, and what DAPA-HF and related trials tell us about brain health outcomes.
Read clinical reviewA physician-reviewed comparison of compounded dapagliflozin versus branded Farxiga covering safety, efficacy data, regulatory status, cost, and clinical decision-making.
Read clinical reviewA GRADE-graded review of the dapagliflozin (Farxiga) evidence base across type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. Primary-literature citations, effect sizes, and clinical decision guidance.
Read clinical reviewA physician-reviewed guide to dapagliflozin (Farxiga) hair loss and skin changes, including genital mycotic infections, rash incidence from clinical trials, and what to do if symptoms appear.
Read clinical reviewA clinician-level review of how dapagliflozin (Farxiga) affects liver enzymes, hepatic steatosis, and fibrosis markers, with primary-literature citations and dosing guidance for patients with hepatic impairment.
Read clinical reviewA clinical deep-dive into how dapagliflozin (Farxiga) affects mental health, mood, depression risk, and quality of life. Covers DAPA-HF, DAPA-CKD, and emerging mechanistic data with physician-level citations.
Read clinical reviewA physician-reviewed deep dive into how dapagliflozin (Farxiga) alters glucose metabolism, substrate oxidation, and energy expenditure in type 2 diabetes, heart failure, and CKD, with primary-literature citations.
Read clinical reviewA clinician-level review of dapagliflozin (Farxiga) dosing, the evidence for sub-standard doses, heart failure and CKD data, and how to apply dose-selection logic in practice.
Read clinical reviewEvidence-based guide to muscle preservation strategies for patients on Farxiga (dapagliflozin), covering the mechanistic rationale, clinical trial data, and actionable co-interventions to protect lean mass.
Read clinical reviewWhy dapagliflozin (Farxiga) stops working, and what to do about it. MD/PharmD-level analysis of glycemic plateaus, HF non-response, CKD progression, and evidence-based escalation strategies.
Read clinical reviewEvidence-based guidance on the dapagliflozin pre-surgery hold window, including how long to stop Farxiga before procedures, why SGLT2 inhibitor-associated ketoacidosis matters, and what the latest guidelines say.
Read clinical reviewStopping Farxiga (dapagliflozin) can trigger fluid retention, blood sugar rebound, and worsening heart failure within days. This evidence-based guide covers the mechanism, timelines, clinical trial data, and how to stop safely.
Read clinical reviewA physician-reviewed, evidence-based guide to dapagliflozin (Farxiga) and kidney outcomes, covering DAPA-CKD, DAPA-HF, CREDENCE, and the mechanisms behind SGLT2-inhibitor renal protection and risk.
Read clinical reviewWhen and how to safely restart dapagliflozin (Farxiga) after acute illness, surgery, or hospitalization. Evidence-based guidance with dose timing, DKA risk thresholds, and a step-by-step restart checklist.
Read clinical reviewClinician-level review of how heat, cold, dehydration, infection risk, and seasonal illness affect Farxiga (dapagliflozin) safety and dosing across all four seasons, with primary-literature citations.
Read clinical reviewA physician-reviewed guide to how dapagliflozin (Farxiga) affects sexual function in men and women with type 2 diabetes, heart failure, and CKD, including trial data, mechanistic explanations, and clinical management of genital mycotic infections.
Read clinical reviewA clinician-level review of how dapagliflozin (Farxiga) affects sleep architecture, nocturia, OSA-related outcomes, and cardiorespiratory physiology, with primary-literature citations.
Read clinical reviewComplete MD/PharmD-level guidance on managing dapagliflozin (Farxiga) dosing during travel, timezone shifts, long-haul flights, and destination-specific risks. Includes SGLT2 inhibitor sick-day rules, DKA prevention, and hydration protocols.
Read clinical review